Search

Uptravi

Uptravi

selexipag

Manufacturer:

Janssen

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Selexipag
Indications/Uses
Long-term treatment of pulmonary arterial HTN (PAH) in adult patients w/ WHO functional class II-III, including idiopathic & heritable PAH, PAH associated w/ connective tissue disorders, & PAH associated w/ corrected simple congenital heart disease, either as combination therapy in patients insufficiently controlled w/ endothelin receptor antagonist &/or phosphodiesterase type 5 inhibitor, or as monotherapy in patients who are not candidates for these therapies.
Click to view Uptravi detailed prescribing information
Dosage/Direction for Use
Initially 200 mcg bd, approx 12 hr apart. May be increased in increments of 200 mcg bd, usually at wkly intervals. Max: 1,600 mcg bd.
Click to view Uptravi detailed prescribing information
Overdosage
View Uptravi overdosage for action to be taken in the event of an overdose.
Administration
May be taken with or without food: Take consistently w/ or w/o food. Swallow whole, do not chew/split/crush.
Contraindications
Hypersensitivity. Severe CHD or unstable angina, MI w/in last 6 mth; decompensated cardiac failure, severe arrhythmias; cerebrovascular events (eg, transient ischaemic attack, stroke) w/in last 3 mth; congenital or acquired valvular defects w/ clinically relevant myocardial function disorders not related to pulmonary HTN. Concomitant use of strong CYP2C8 inhibitors eg, gemfibrozil. Severe hepatic impairment (Child-Pugh class C).
Click to view Uptravi detailed prescribing information
Special Precautions
Hypotension, monitor BP. Increased heart rate. Hyperthyroidism, perform thyroid function tests as clinically indicated. Pulmonary veno-occlusive disease, discontinue if confirmed. Severe renal impairment, caution should be exercised during dose titration. Avoid use during pregnancy. Not recommended during lactation.
Click to view Uptravi detailed prescribing information
Adverse Reactions
Headache, diarrhoea, nausea & vomiting, jaw pain, myalgia, pain in extremity, flushing, arthralgia.
Click to view Uptravi detailed prescribing information
Drug Interactions
Increased exposure w/ lopinavir/ritonavir. Increased exposure w/ inhibitors of UGT1A3 & UGT2B7. Increased exposure of selexipag actia metabolite w/ CYP2C8 inhibitors. Hormonal contraceptives.
Click to view Uptravi detailed prescribing information
Caution For Usage
For caution against possible variation of physical aspect of medicine... Click to view Uptravi detailed prescribing information
Storage
View Uptravi storage conditions for details to ensure optimal shelf-life.
Description
View Uptravi description for details of the chemical structure and excipients (inactive components).
Action
View Uptravi mechanism of action for pharmacodynamics and pharmacokinetics details.
MIMS Class
Other Antihypertensives
ATC Classification
B01AC27 - selexipag ; Belongs to the class of platelet aggregation inhibitors excluding heparin. Used in the treatment of thrombosis.
Presentation/Packing
Form
Uptravi FC tab 1,000 mcg
Packing/Price
60's
Form
Uptravi FC tab 1,200 mcg
Packing/Price
60's
Form
Uptravi FC tab 1,400 mcg
Packing/Price
60's
Form
Uptravi FC tab 1,600 mcg
Packing/Price
60's
Form
Uptravi FC tab 200 mcg
Packing/Price
140's;60's
Form
Uptravi FC tab 400 mcg
Packing/Price
60's
Form
Uptravi FC tab 600 mcg
Packing/Price
60's
Form
Uptravi FC tab 800 mcg
Packing/Price
60's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in